Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Sequana Medical    SEQUA   BE0974340722

SEQUANA MEDICAL

(SEQUA)
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
09/16/2019 09/17/2019 09/18/2019 09/19/2019 09/20/2019 Date
7.2(c) 7.1(c) 7.1(c) 7.14(c) 7.28(c) Last
1 035 586 580 7 401 617 Volume
-1.10% -1.39% 0.00% +0.56% +1.96% Change
More quotes
Financials (EUR)
Sales 2019 2,00 M
EBIT 2019 -12,1 M
Net income 2019 -12,6 M
Debt 2019 7,90 M
Yield 2019 -
Sales 2020 3,30 M
EBIT 2020 -11,1 M
Net income 2020 -11,6 M
Debt 2020 9,10 M
Yield 2020 -
P/E ratio 2019 -7,28x
P/E ratio 2020 -7,91x
EV / Sales2019 61,6x
EV / Sales2020 37,7x
Capitalization 115 M
More Financials
Company
More about the company
Latest news on SEQUANA MEDICAL
06/04Sequana Medical Announces Unconditional IDE Approval from U.S. FDA to Start a..
GL
05/28SEQUANA MEDICAL : Announces Presentation of Positive DSR Clinical Proof-of-Conce..
AQ
05/27SEQUANA MEDICAL : Announces Presentation of Positive DSR Clinical Proof-of-Conce..
AQ
04/05SEQUANA MEDICAL : announces 2018 Full Year Results and 2019 Outlook
AQ
02/12SEQUANA MEDICAL : lists on Euronext Brussels
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
09/20Brazil Announces Criminal Charges Against 7 Vale Employees in Dam Collapse--U..
DJ
09/20REGENERON PHARMACEUTICALS : Sanofi Get Positive CHMP Opinion for Dupixent
DJ
09/19Animal health sector aims to emulate Zoetis biotech leap
RE
09/18BIOGEN : to Study Higher Dose of Spinraza in Spinal Muscular Atrophy
DJ
09/16A Plan to Fight Hep C -- WSJ
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart SEQUANA MEDICAL
Duration : Period :
Sequana Medical Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SEQUANA MEDICAL
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 13,10  €
Last Close Price 7,28  €
Spread / Highest target 85,4%
Spread / Average Target 79,9%
Spread / Lowest Target 74,5%
EPS Revisions
Managers
NameTitle
Chief Executive Officer
Chairman
Chief Financial Officer
Chief Medial Officer
Rudy Dekeyser Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
SEQUANA MEDICAL0.00%127
IQVIA HOLDINGS INC33.94%30 481
LONZA GROUP35.89%25 846
CELLTRION, INC.--.--%18 845
INCYTE CORPORATION22.85%17 466
EXACT SCIENCES CORPORATION64.77%13 463